We estimate that the CEO of MBX Biosciences, Inc. ($MBX), P. Kent Hawryluk, received a compensation of $2,990,867 in 2025. This is an increase of 25.26% from an estimated $2,235,317 in 2024.
These estimates are based on a new DEF14A filing, filed with the SEC on April 22, 2026. Note that parsing errors may occur.
You can track $MBX on Quiver Quantitative's $MBX stock dashboard.
$MBX Stock Insider Trading Activity
$MBX Stock insiders have traded $MBX stock on the open market 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $MBX stock by insiders over the last 6 months:
- P. KENT HAWRYLUK (President & CEO) purchased 18,500 shares for an estimated $525,662
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$MBX Stock Hedge Fund Activity
We have seen 90 institutional investors add shares of $MBX Stock stock to their portfolio, and 51 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- WELLINGTON MANAGEMENT GROUP LLP removed 1,473,375 shares (-30.5%) from their portfolio in Q4 2025, for an estimated $46,470,247
- FRANKLIN RESOURCES INC removed 1,307,288 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $41,231,863
- AARON WEALTH ADVISORS LLC added 1,098,176 shares (+1568.8%) to their portfolio in Q1 2026, for an estimated $32,780,553
- KYNAM CAPITAL MANAGEMENT, LP removed 1,065,201 shares (-53.3%) from their portfolio in Q4 2025, for an estimated $33,596,439
- BRAIDWELL LP added 1,018,600 shares (+inf%) to their portfolio in Q4 2025, for an estimated $32,126,644
- BLACKROCK, INC. added 962,295 shares (+49.2%) to their portfolio in Q4 2025, for an estimated $30,350,784
- EVENTIDE ASSET MANAGEMENT, LLC added 890,000 shares (+inf%) to their portfolio in Q4 2025, for an estimated $28,070,600
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$MBX Stock Analyst Ratings
Wall Street analysts have issued reports on $MBX in the last several months. We have seen 4 firms issue buy ratings on the stock, and 1 firms issue sell ratings.
Here are some recent analyst ratings:
- UBS issued a "Buy" rating on 01/07/2026
- Stifel issued a "Buy" rating on 12/19/2025
- Goldman Sachs issued a "Sell" rating on 12/04/2025
- Guggenheim issued a "Buy" rating on 11/10/2025
- TD Cowen issued a "Buy" rating on 11/04/2025
To track analyst ratings and price targets for $MBX Stock, check out Quiver Quantitative's $MBX forecast page.
$MBX Stock Price Targets
Multiple analysts have issued price targets for $MBX recently. We have seen 5 analysts offer price targets for $MBX in the last 6 months, with a median target of $60.0.
Here are some recent targets:
- Eliana Merle from Barclays set a target price of $66.0 on 01/28/2026
- Seamus Fernandez from Guggenheim set a target price of $88.0 on 01/16/2026
- Michael Yee from UBS set a target price of $60.0 on 01/07/2026
- Annabel Samimy from Stifel set a target price of $50.0 on 12/19/2025
- Corinne Johnson from Goldman Sachs set a target price of $18.0 on 12/04/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
